Skip to content

Adarx Pharmaceuticals

US · ADRX #2823 by market cap Listed 2026
12.79 -1.37 -9.68%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 2.75 Expensive vs history 98th percentile
5-year average -6.01 · #295 of 514 in Biotechnology
P/E ratio -15.52 Expensive vs history 85th percentile
5-year average -18.37 · forward -9.05
P/S ratio 257.70 Cheap vs history 25th percentile
5-year average 265.31 · forward 513.93 · #323 of 389 in Biotechnology

Vs. peers Biotechnology

Company Market cap P/E (TTM) P/B Div yield
Adarx Pharmaceuticals (ADRX) 1.42B -13.98 2.48 0.00%
Vertex Pharmaceuticals (VRTX) 130.58B 33.14 6.25 0.00%
Regeneron Pharmaceuticals (REGN) 95.24B 20.35 2.84 0.40%
Moderna (MRNA) 78.90B -27.70 11.54 0.00%
argenx SE (ARGX) 58.21B 32.06 6.92 0.00%
BeiGene (ONC) 44.66B 49.74 7.67 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value15.28 Economic moatNone UncertaintyVery High

Trading 19.4% below Morningstar's fair value estimate.

Fair value

Adarx Pharmaceuticals Inc is assigned a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% discount to our quantitative fair value estimate of $15.28 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The company's valuation metrics strengthen our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's price to cash ratio of 3.3 falls in the bottom 40% compared with peers globally. Even if the company were to encounter financial distress, its cash balances could allow it to maneuver effectively. We believe this is a sign that shares could be cheap.

On a different note, the company's liquidity is potentially concerning. Excessive liquidity may suggest inefficient capital use or limited investment opportunities. The firm's median trading volume over the past 60 days, a core component of liquidity, lies in the top 40% compared with peers globally. High trading volumes could indicate a sharp change in business model or a new growth trajectory of the business. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:38 · For reference only, not investment advice and not tailored to your situation.

Adarx Pharmaceuticals discussion 0 comments

Add a comment